Broad based screen of possible biomarkers. p53 is included here.
Breast and Gynecologic Cancers Research
The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody biomarkers in breast, prostate, and ovarian cancer. P53-specific gene mutations are frequent in multiple cancer types. Of the common solid tumors, p53 mutations have been identified in 50% of lung and ovarian cancers, 45% of colon cancers, 20% of breast cancers, and 10-30% of prostate cancers (The p53 Mutation Handbook, T. Soussi, http://p53/free/fr). The most common mutations vary from cancer to cancer, with 50 point mutations covering the 10 most common mutations for all major solid tumors
1.B. Project Objectives
Aim 1: Generation of NAPPA protein microarrays expressing the fifty most common p53 point mutations for solid tumors as well as deletion constructs of p53.
Aim 2: Identify p53 mutation-specific antibodies in a test set of breast, prostate, and ovarian cancer patient sera.
a. Using test sera from patients with prostate, ovarian, and breast cancers, identify patient sera that contain anti-p53 antibodies.
b. Using p53-antibody-positive sera from patients, screen the p53 mutation microarray to identify mutation-specific and domain-specific antibodies
c. Using p53-antibody-negative sera from patients, screen the p53 mutation microarray to identify mutation-specific antibodies
d. Determine the sensitivity and specificity of individual antibodies that distinguish patient sera from normal sera.
e. Determine if mutation-specific antibodies can distinguish tumor types.
Various including quantile regression, Fishers exact, binomial proportion and others. The methods are not yet fixed because we are still in discovery.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.
There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (email@example.com) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.
EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.